Arena Pharmaceuticals' APD668 Enters Phase I Clinical Trial for Type 2 Diabetes Treatment

Strategic Insights -

Arena Pharmaceuticals, Inc. (ARNA) announced that Ortho-McNeil, Inc., a Johnson & Johnson company, has initiated a phase I clinical trial of APD668, a novel orally administered drug candidate discovered by Arena for the treatment of Type 2 diabetes. This milestone payment triggers a $5 million payment to Arena under its collaboration with Ortho-McNeil. The collaboration is focused on developing compounds targeting the Glucose-Dependent Insulinotropic Receptor (GDIR), a novel receptor discovered by Arena that has the potential to stimulate insulin production in response to increases in blood glucose.

Key Takeaways:

  • Arena Pharmaceuticals' APD668 has entered a phase I clinical trial for the treatment of Type 2 diabetes, a significant milestone in its development.
  • The collaboration with Ortho-McNeil, a Johnson & Johnson company, has triggered a $5 million milestone payment to Arena.
  • The GDIR is a novel receptor discovered by Arena that has the potential to stimulate insulin production in response to increases in blood glucose.
  • APD668 is a novel, highly potent, and orally active GDIR agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels.
  • The GDIR mechanism is glucose-dependent, meaning it only lowers blood glucose when it rises above normal levels, reducing the risk of hypoglycemia.
  • This collaboration demonstrates Arena's commitment to developing innovative treatments for Type 2 diabetes.
  • Jack Lief, Arena's president and CEO, expressed confidence in the partnership with Ortho-McNeil, stating, "We are very pleased with Ortho-McNeil as a partner and the priority they have placed on this program."

Statistics:

  • $5 million: the milestone payment to Arena under its collaboration with Ortho-McNeil.
  • APSD668: a novel orally administered drug candidate developed by Arena for Type 2 diabetes treatment.
  • 2006: the year in which Ortho-McNeil initiated the phase I clinical trial of APD668.
  • 19AJ receptor: a previously referred to name for the GDIR receptor discovered by Arena.

Sources:

  • Arena Pharmaceuticals, Inc. (ARNA)
  • Ortho-McNeil, Inc.
  • Health & Medicine Week
  • NewsRx.com
  • Copyright 2006, Health & Medicine Week via NewsRx.com.